Opinion

Video

Implications of ESMO Guidelines for IGHV-Mutated vs Unmutated CLL

Author(s):

Carsten Niemann, MD, PhD,Arnon Kater, MD, PhD

A panel of medical experts provides an overview of recent ESMO guideline updates on frontline management for patients with IGHV-mutated or unmutated chronic lymphocytic leukemia (CLL) without TP53 mutations, highlighting key clinical implications.

Video content above is prompted by the following:

  • Briefly review recent ESMO guideline updates for the frontline management of patients with IGHV-unmutated or mutated and no TP53 mutation and discuss associated implications.
Related Videos
4 experts are featured in this series.
2 expert is featured in this series.
4 experts are featured in this series.
2 expert is featured in this series.
Related Content
Chronic Lymphocytic Leukemia | Image Credit: © LAZLO- stock.adobe.com
January 8th 2025

Fixed-Duration Zanubrutinib/Venetoclax Shows Efficacy in R/R Chronic Lymphocytic Leukemia

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Sonrotoclax Plus Zanubrutinib Generates Responses in Treatment-Naive CLL/SLL
December 19th 2024

Venetoclax-Based Therapy Is Associated With Worse Outcomes in BTK Inhibitor–Resistant, Chemo-Naive CLL

Talal Hilal, MD, MB, BCh
January 12th 2023

Hilal Highlights BTK Inhibitor Research and Implications of MRD Negativity in CLL

Chronic Lymphocytic Leukemia | stock.adobe.com
December 10th 2024

Pirtobrutinib Improves PFS in Previously Treated CLL/SLL

Chronic Lymphocytic Leukemia | © LAZLO- stock.adobe.com
December 10th 2024

First-Line Pirtobrutinib Plus Venetoclax/Obinutuzumab Generates High uMRD Rates in CLL